Table 2.
Characteristics of the 33 patients from the Salpêtrière database for whom the impact of EGFR amplification and CDKN2A locus homozygous deletion was assessed.
| Characteristics of the 33 patients of the independent dataset | |
|---|---|
| Number of patients | 33 |
| Median age (years) at diagnosis (range) | 59 (25–81) |
| Initial treatment (%) | RTCT (100%) |
| Median delay (months) between diagnosis and bev./iri. onset (range) | 15 (3.5–60) |
| Recurrence number at bev./iri. onset | |
| First | 31 |
| Second/third | 1/1 |
| Response according to RANO | |
| Complete | 4 |
| Partial | 11 |
| Stable | 7 |
| Progression | 7 |
| Not assessable | 3 |
| EGFR amplification | 13 |
| CDKN2A homozygous deletion | 12 |
| Median PFS after bev./iri. onset (months) | 5.5 |
| Median OS after bev./iri. onset (months) | 9.7 |
| Median OS since diagnosis (months) | 29 |
RTCT: temozolomide radiochemotherapy; bev./iri.: bevacizumab/irinotecan chemotherapy; KPS: Karnofsky performance status; PFS: progression-free survival; OS: overall survival; ns, nonsignificant.